Protalix BioTherapeutics, Inc.
No SEC Form 4 filings for $PLX in the last 30 days.
See all $PLX insider activity →Protalix BioTherapeutics, Inc. (PLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 plx-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT ● Revenues from selling goods increased to $19.8 million in the se
Protalix BioTherapeutics, Inc. (PLX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 plx-20260625xex10d1.htm EX-10.1 Exhibit 10.1 PROTALIX BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN ( Amended and Restated as of June 25, 2026 ) 1. Purposes of the Plan . The purposes of this Plan are to attract and retain the best available per
Protalix BioTherapeutics (PLX) has announced its 2026 annual stockholder meeting to be held on June 25, 2026, in Tel Aviv. Key agenda items include the election of eight directors, a non-binding advisory vote on executive compensation, and the approval of an amended 2006 Stock Incentive Plan to increase the share reserve by 3.5 million to 20,975,171 shares. The company also reported CEO Dror Bashan's 2025 compensation of $1.17 million and outlined change-in-control benefits for executives.
Over the past 7 days, alphai's AI scored 1 news story mentioning PLX (Protalix BioTherapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PLX coverage spans financial news, earnings and corporate actions.
The filing provides fresh, trade-relevant updates on commercial revenue trajectory, cash runway, and the timing of PRX-115 top-line readout (2H 2027).
The filing is a corporate-governance/compensation-plan update; it may affect dilution expectations and equity overhang, but no deal or financial guidance is disclosed.
The announcement of the 2026 shareholder meeting, director elections, and stock plan amendments may influence investor sentiment and stock price.
The European Medicines Agency's (EMA) negative opinion on Elfabrio's dosing schedule for Fabry disease has led to a decline in Protalix BioTherapeutics stock. This regulatory setback introduces short-term downside risk, especially considering the company's reliance on EMA approvals for product success.
alphai scores every news story that mentions PLX with an AI model for sentiment and relevance, and aggregates insider trades from Protalix BioTherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Protalix BioTherapeutics, Inc. (PLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 plx-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT ● Revenues from selling goods increased to $19.8 million in the se
6 min readProtalix BioTherapeutics, Inc. (PLX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 plx-20260625xex10d1.htm EX-10.1 Exhibit 10.1 PROTALIX BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2006 STOCK INCENTIVE PLAN ( Amended and Restated as of June 25, 2026 ) 1. Purposes of the Plan . The purposes of this Plan are to attract and retain the best available per
2 min readProtalix BioTherapeutics (PLX) has announced its 2026 annual stockholder meeting to be held on June 25, 2026, in Tel Aviv. Key agenda items include the election of eight directors, a non-binding advisory vote on executive compensation, and the approval of an amended 2006 Stock Incentive Plan to increase the share reserve by 3.5 million to 20,975,171 shares. The company also reported CEO Dror Bashan's 2025 compensation of $1.17 million and outlined change-in-control benefits for executives.
3 min readThe Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a negative opinion for Protalix BioTherapeutics, Inc.'s ( NYSE:PLX ) and Chiesi Group's partnered Elfabrio's revised dosing schedule for Fabry disease.
4 min read
